Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | S100B | P04271 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762658 | 0.98 | LPL (0.43) | LPLLIPGPRMT6MEN1KMT2A | |
| SCHEMBL2192867 | 0.98 | LPL (0.43) | LPLLIPGPRMT6MEN1KMT2A | |
| SCHEMBL1701553 | 0.97 | LPL (0.44) | LPLLIPGPRMT6MEN1KMT2A | |
| SCHEMBL2192979 | 0.89 | KMO (0.42) | LPLLIPGMEN1KMT2AALDH1A1 | |
| SCHEMBL2940900 | 0.88 | ADRA2C (0.51) | LPLLIPGMEN1KMT2AGAA | |
| SCHEMBL17698396 | 0.88 | LIPG (0.43) | LPLLIPGIRAK4ADRA2CROCK1 | |
| SCHEMBL31298214 | 0.88 | ADRA2C (0.51) | LPLLIPGMEN1KMT2AGAA | |
| SCHEMBL29790026 | 0.88 | LMNA (0.46) | LPLLIPGMEN1KMT2AALDH1A1 | |
| SCHEMBL856181 | 0.88 | LMNA (0.46) | LPLLIPGMEN1KMT2AALDH1A1 | |
| SCHEMBL26510394 | 0.88 | ADRB1 (0.48) | ALDH1A1MAPTHTTADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327375-A1 | SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | ADDEX PHARMA S.A. (CH) | 2024-10-03 | — | — | US | disclosed |
| CN-114025847-B | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4337643-A1 | SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | Addex Pharma S.A (CH) | 2024-03-20 | — | — | EP | disclosed |
| CN-117597331-A | Substituted heterobicyclic derivatives as MGLU7 receptor negative allosteric modulators | 阿德克斯法尔马股份公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4217342-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | Neuropore Therapies, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116507607-A | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20220298155-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-11299487-B2 | Compounds and compositions as modulators of TLR signaling | NEUROPORE THERAPIES, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| WO-2022067114-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-2512242-A1 | NOVEL COMPOUNDS | Glaxo Wellcome Manufacturing Pte Ltd (SG) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252805-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| EP-2403833-A1 | 8-SUBSTITUTED QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-2011075559-A1 | NOVEL COMPOUNDS | GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) | 2011-06-23 | — | — | WO | disclosed |
| WO-2010146173-A1 | QUINAZOLINE DERIVATIVES AS HISTAMINE H4-RECEPT0R INHIBITORS FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-12-23 | — | — | WO | disclosed |
| EP-2242756-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| WO-2010101949-A1 | 8-SUBSTITUTED QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010101949-A1 | 8-SUBSTITUTED QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252805-A1 | NOVEL COMPOUNDS | CYBB, NOX1, NOX4 | LPL 1263/4885LIPG 420/4885PRMT6 1685/4885 |
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | LPL 283/4885LIPG 446/4885PRMT6 3099/4885 |
| US-20220298155-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | LPL 283/4885LIPG 446/4885PRMT6 3099/4885 |
| US-20240327375-A1 | SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | GRM7, GRM2, GRM1 | LPL 4466/4885LIPG 4638/4885PRMT6 503/4885 |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | LPL 2217/4885LIPG 2295/4885PRMT6 1956/4885 |
| US-11299487-B2 | Compounds and compositions as modulators of TLR signaling | TLR3, TLR6, TLR4 | LPL 335/4885LIPG 515/4885PRMT6 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.